GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) help people sustain lower calorie intake for more than a year, according to recent research on how these drugs work in the body.
The medications reduce appetite by slowing stomach emptying and triggering satiety signals in the brain. Users report feeling full faster and staying satisfied longer, which naturally leads to eating fewer calories without requiring constant willpower or strict dieting.
Studies tracking patients over 12 months or longer show the appetite-suppressing effect persists rather than wearing off over time. This sustained reduction in food intake drives weight loss and helps maintain that loss, distinguishing GLP-1s from older weight loss medications that often lose effectiveness as the body adapts.
The mechanism works through multiple pathways. These drugs mimic glucagon-like peptide-1, a hormone your body naturally produces after eating. By enhancing this signal, they make portions feel adequate at smaller sizes and reduce cravings for high-calorie foods. The effect occurs in the hypothalamus, your brain's appetite control center, plus the stomach and intestines.
Researchers note the sustained appetite suppression explains why many patients find weight loss easier to maintain on these medications compared to diet alone. When people stop taking GLP-1s, appetite typically returns and weight often rebounds, underscoring that these are ongoing treatments rather than one-time solutions.
For people considering GLP-1 therapy, the evidence suggests the initial appetite reduction remains reliable over extended periods. Side effects like nausea typically improve after the first few weeks, while the appetite suppression continues. Cost and access remain barriers for many, since most insurers restrict coverage to people with diabetes or obesity-related conditions.
The research supports GLP-1s as effective